



501-3292 Production Way, Burnaby, B.C., V5A 4R4

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Makes Significant Breakthrough in FAIMS Technology Development

Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety

Vancouver, British Columbia, March 2, 2020 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that a significant technological development has been achieved with its FAIMS- (field asymmetric waveform ion mobility spectrometry) marijuana breathalyzer prototype. Cannabix scientists have been characterizing the device for several months to increase resolving power and sensitivity. The Company is pleased to report that the Beta 3.1 FAIMS device has achieved ion-resolving levels that enable the isolation of $\Delta 9$ -tetrahydrocannabinol (“THC”) in human breath and suppress background compounds effectively. With human subject breath testing performed up to 90 minutes after smoking marijuana and nicotine cigarettes, the Cannabix FAIMS device was able to selectively isolate THC or nicotine and suppress unwanted background volatile organic compounds. In addition, metabolites for both cannabis and nicotine were detected. Subject testing up to 90 minutes after smoking was accomplished using only a few breath samples from the test subject. The characterization work and recent developments were conducted using a bench version of the Beta 3.1 FAIMS device coupled to mass spectrometer for validation. A number of factors including FAIMS cell geometry, flow optimization and ion-focusing techniques have contributed to this latest development.

“I’m impressed with the progress that has been made by the Cannabix team in the development of this newest version; the sensitivity and selectivity is impressive. I look forward to continued collaborations between UF and Cannabix to advance FAIMS detection.” says Dr. Richard Yost, Cannabix Scientific Advisor.

“We are very excited about our recent results on being able to consistently resolve THC and other analytes from breath. It is hard to overstate the significance of these achievements in atmospheric conditions (without vacuum). These key steps will result in a new type of device that the analytical and diagnostic fields have been seeking for breath analysis.” says Dr. Raj Attariwala, Chief Scientific Officer

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In

particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.